Company profile for Fermion Oy

Fermion-PSE
News

DATA COMPILATION
#PharmaFlow

PharmaCompass

With Fermion, start the journey of your innovative API.

Related CompaniesRelated Companies

About

Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Finland
Address
Address
Koivu-Mankkaan tie 6 A, FI-02200 Espoo
Telephone
Telephone
+358 104261
Twitter
Twitter
Contact Info
Others

Events

Webinars & Exhibitions

cphi-india-2024-91846.png

CPhI India 2024

Contact Supplier

Meeting

Digital content read-more

Explore the latest content creation from this company

CORPORATE CONTENT #SupplierSpotlight

    https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-40979.pdf

    https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-1647319060.pdf

    https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-43677.pdf

    https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-1647319463.pdf

    https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-1647319373.pdf

    https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-1647319203.pdf

DATA COMPILATION #PharmaFlow

read-more
read-more
CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities
During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 

Impressions: 2793

https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

#PharmaFlow by PHARMACOMPASS
08 Aug 2024

NEWS #PharmaBuzz

read-more
read-more
Green chemistry at Fermion
Green chemistry at Fermion

20 Aug 2024

// PRESS RELEASE

https://www.fermion.fi/who-we-are/news/green-chemistry/

PRESS RELEASE
20 Aug 2024

https://www.fermion.fi/who-we-are/news/fermion-has-completed-first-investment-for-new-manufacturing-capacity-for-apis-at-its-hanko-site/

PRFESS RELEASE
12 Mar 2024

https://www.indianpharmapost.com/news/ami-organics-inks-agreement-with-fermion-for-two-additional-apis-15027

INDIAN PHARMA POST
19 Dec 2023

https://www.fermion.fi/who-we-are/news/fermion-has-received-ceps-for-benserazide-hcl-and-entacapone/

PRESS RELEASE
19 Oct 2023
Solar energy for Fermion’s Hanko plant
Solar energy for Fermion’s Hanko plant

18 Sep 2023

// PRESS RELEASE

https://www.fermion.fi/who-we-are/news/solar-energy-for-fermions-hanko-plant/

PRESS RELEASE
18 Sep 2023

https://www.indianpharmapost.com/news/ami-organics-to-supply-additional-api-to-fermion-14666

INDIANPHARMAPOST
15 Sep 2023

USDMF

read-more
read-more

01

GDUFA

DMF Review : Complete

Rev. Date : 2016-07-22

Pay. Date : 2016-06-23

DMF Number : 15249

Submission : 2001-01-15

Status : Active

Type : II

fermion

02

GDUFA

DMF Review : Complete

Rev. Date : 2020-12-30

Pay. Date : 2020-12-23

DMF Number : 9043

Submission : 1991-04-04

Status : Active

Type : II

fermion

03

GDUFA

DMF Review : Complete

Rev. Date : 2016-09-14

Pay. Date : 2016-08-29

DMF Number : 5408

Submission : 1984-03-19

Status : Active

Type : II

fermion

04

GDUFA

DMF Review : Complete

Rev. Date : 2016-07-28

Pay. Date : 2016-07-21

DMF Number : 11148

Submission : 1994-10-21

Status : Active

Type : II

fermion

05

GDUFA

DMF Review : Complete

Rev. Date : 2020-04-17

Pay. Date : 2020-02-27

DMF Number : 34437

Submission : 2020-02-25

Status : Active

Type : II

fermion

06

GDUFA

DMF Review : Complete

Rev. Date : 2013-11-20

Pay. Date : 2013-05-10

DMF Number : 26416

Submission : 2012-09-14

Status : Active

Type : II

fermion

07

GDUFA

DMF Review : Complete

Rev. Date : 2018-06-13

Pay. Date : 2018-02-08

DMF Number : 10006

Submission : 1992-12-15

Status : Active

Type : II

fermion

08

GDUFA

DMF Review : Complete

Rev. Date : 2021-08-31

Pay. Date : 2021-08-26

DMF Number : 13810

Submission : 1998-10-30

Status : Active

Type : II

fermion

09

GDUFA

DMF Review : Complete

Rev. Date : 2017-02-01

Pay. Date : 2016-12-29

DMF Number : 5717

Submission : 1985-02-06

Status : Active

Type : II

fermion

10

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 12444

Submission : 1997-03-26

Status : Active

Type : II

fermion
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KEY PRODUCTS

read-more
read-more

TOP RANKED SUPPLIER FOR:

Sponsored Ads.
full-view
Sponsored Ads.full-view
Sponsored Ads.full-view
Sponsored Ads.full-view
Sponsored Ads.full-view

Services

Discover the service capabilities from this company

Analytical

Discover their expertise for : Analytical

API Manufacturing

Discover their expertise for : API Manufacturing

Drug Product Manufacturing

Discover their expertise for : Drug Product Manufacturing

API & Drug Product Development

Discover their expertise for : API & Drug Product Development

Packaging

Discover their expertise for : Packaging

KEY SERVICES

read-more
read-more

TOP RANKED SUPPLIER FOR:

Clinical Phases to Recurrent Production
full-view
cGMP Contract Manufacturing of API
full-view
Opiate Based Controlled Substances
full-view
CDMO for Cytotoxic Compounds
full-view
Aseptic Micronization
full-view
Gels In Liquid Stick Packs
full-view

Inspections and registrations

Check the inspections & registration from this company

ABOUT THIS PAGE

Contact Fermion Oy and get a quotation

Fermion Oy is a supplier offers 39 products (APIs, Excipients or Intermediates).

Find a price of Alprazolam bulk with DMF, CEP, JDMF offered by Fermion Oy

Find a price of Azathioprine bulk with DMF, CEP, JDMF offered by Fermion Oy

Find a price of Formoterol Fumarate bulk with DMF, CEP, JDMF offered by Fermion Oy

Find a price of Hydroxychloroquine Sulphate bulk with DMF, CEP, JDMF offered by Fermion Oy

Find a price of Irinotecan Hydrochloride bulk with DMF, CEP, JDMF offered by Fermion Oy

Find a price of Mercaptopurine bulk with DMF, CEP, JDMF offered by Fermion Oy

Find a price of Methotrexate bulk with DMF, CEP, JDMF offered by Fermion Oy

Find a price of Sodium Cromoglicate bulk with DMF, CEP, JDMF offered by Fermion Oy

Find a price of Buspirone Hydrochloride bulk with DMF, CEP offered by Fermion Oy

Find a price of Carbidopa bulk with DMF, CEP offered by Fermion Oy

Find a price of Dexmedetomidine Hydrochloride bulk with DMF, JDMF offered by Fermion Oy

Find a price of Entacapone bulk with DMF, CEP offered by Fermion Oy

Find a price of Fluoxetine Hydrochloride bulk with DMF, CEP offered by Fermion Oy

Find a price of Flutamide bulk with DMF, CEP offered by Fermion Oy

Find a price of Nadolol bulk with DMF, JDMF offered by Fermion Oy

Find a price of Nitrofurantoin bulk with DMF, CEP offered by Fermion Oy

Find a price of Propafenone Hydrochloride bulk with DMF, CEP offered by Fermion Oy

Find a price of Quetiapine Hemifumarate bulk with DMF, CEP offered by Fermion Oy

Find a price of Toremifene Citrate bulk with DMF, JDMF offered by Fermion Oy

Find a price of Benserazide Hydrochloride bulk with CEP offered by Fermion Oy

Find a price of Budesonide bulk with CEP offered by Fermion Oy

Find a price of Cabozantinib bulk with DMF offered by Fermion Oy

Find a price of Diltiazem Hydrochloride bulk with DMF offered by Fermion Oy

Find a price of Glipizide bulk with DMF offered by Fermion Oy

Find a price of Levosimendan bulk with DMF offered by Fermion Oy

Find a price of Methotrexate bulk with DMF offered by Fermion Oy

Find a price of Nintedanib Esylate bulk with DMF offered by Fermion Oy

Find a price of Nitrofurantoin bulk with DMF offered by Fermion Oy

Find a price of Ospemifene bulk with DMF offered by Fermion Oy

Find a price of Quetiapine Hemifumarate bulk with DMF offered by Fermion Oy

Find a price of Salmeterol Xinafoate bulk with CEP offered by Fermion Oy

Find a price of Tamsulosin bulk with JDMF offered by Fermion Oy

Find a price of Tolnaftate bulk with DMF offered by Fermion Oy

Find a price of Trazodone Hydrochloride bulk with DMF offered by Fermion Oy

Find a price of Treosulfan bulk with DMF offered by Fermion Oy

Find a price of Dabrafenib Mesylate bulk offered by Fermion Oy

Find a price of Osimertinib Mesylate bulk offered by Fermion Oy

Find a price of Rucaparib Camsylate bulk offered by Fermion Oy

Find a price of Vismodegib bulk offered by Fermion Oy

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty